Medical/Pharmaceuticals

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...

2021-02-19 21:00 6147

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2021 Financial Results

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial ...

2021-02-19 20:00 14810

Galderma online survey reveals essential COVID-19 mask wearing can be worsening rosacea skin disease

- Although essential for public health, new online survey findings show that people with self-reported rosacea* may be experiencing worsening of symptoms due to mask wearing, further increasing the daily burden for people living with this chronic skin disease - Despite worsening of signs and sym...

2021-02-19 14:00 2348

Psychobiotic PS128 consumption shows benefits to Parkinson's symptoms in new clinical study

TAIPEI, Feb. 18, 2021 /PRNewswire/ -- Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr.Chin-Song Lu, a renowned researcher for PD i...

2021-02-19 12:07 2083

Regor Therapeutics Announces Completion of $90 Million Series B Financing

SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of$90 million Series B financing. Founded in July of...

2021-02-19 08:00 6424

GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology

NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...

2021-02-18 22:00 2221

BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

SIGNIFICANT ADVANCEMENT TOWARDS LAUNCH OF PHASE I OVARIAN CANCER VACCINE TRIAL VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term Sheet") with BioElpida S.A.S. ...

2021-02-18 21:00 5893

United Imaging Announces Agreement with Vizient for Computed Tomography Systems.

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced an agreement to offer its suite of cutting-edge Computed Tomography technology to Vizient members at contracted pricing. For maximum clinical flexibility, all ...

2021-02-18 21:00 2046

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-02-18 12:26 7123

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-02-18 12:21 3934

First Cancer Early Screening Company Listed on HKEX as New Horizon Health Debuts

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Qiming's portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company. The issue price is HK$26.66 per share; the stock open...

2021-02-18 12:11 7345

Seegene's saliva test for COVID-19 is just as effective as NPS test

SEOUL, South Korea, Feb.18, 2021 /PRNewswire/ -- A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen. A research team at the Department of Laboratory Medicine at Kangwon National University School of Medicine,...

2021-02-18 11:43 2396

Luye Pharma and Towa Pharmaceutical Enter Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan

BASEL, Switzerland, Feb. 18, 2021 /PRNewswire/ -- Luye Pharma Group announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Towa Pharmaceutical Co., Ltd. (Towa), the terms of which grant Towa exclusive rights to the development and commercialization of Rivastig...

2021-02-18 11:24 3651

Vax-Immune Diagnostics Takes Innovative Women's Health Diagnostic Device to European Markets to Improve Maternal Group B Strep Testing Processes

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- Vax-Immune Diagnostics announces today it has received CE Mark approval for its first-in-class medical device, LabReady® GBS.LabReady's Group B Strep product is the first in Vax-Immune Diagnostics' lineup of women's health solutions that helps avoid life-th...

2021-02-18 01:03 1801

EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

PROVIDENCE, R.I., Feb. 18, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU,India, and United States (funded by the EU and India) with the aim of develop...

2021-02-18 01:01 2596

New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children

National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort t...

2021-02-17 21:35 1950

RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107

- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in...

2021-02-17 20:00 4322

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF,Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary ofGermany-based CNS clinical development...

2021-02-17 19:00 6482

Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research

Timely presentations of trial data will accelerate transition from research to practice LUGANO, Switzerland, Feb. 17, 2021 /PRNewswire/ -- ESMO, the leading organisation for medical oncology, launches an important new service for rapidly disseminating research to accelerate the transition of res...

2021-02-17 13:00 1682

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier,France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells. The undisclosed ...

2021-02-17 13:00 1866
1 ... 624625626627628629630 ... 645

Week's Top Stories